Oruka Therapeutics, Inc. (ORKA) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Oruka Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
High 98.00 at 4:30 am ET, low 94.96 at 2:45 pm ET.
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Our mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice per year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases.
the bull case· 1
+22.59%
change in shares held by the ten largest reporting managers over the latest quarter
13fJun 30 '26the bear case· 4
4
of the funds on file reporting a position in ORKA
n-portas of Jun 30 '261.38%
of State Street SPDR S&P Biotech ETF's assets the largest fund weight on file
n-portJun 30 '265 of 20
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '2630
managers whose positions together make up four fifths of the reported value
13fJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 5 '26 report. Not a forecast, not advice.
Of the 6 companies Oruka Therapeutics, Inc. moves with most closely, none share its SEC classification.
Measured against 499 trading days of our own closes. Co-movement, not cause.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
256 managers report a position worth $7.1B between them, and 30 of them hold 80% of it.
tall tick = annual report · 1 on record
ORKA (Oruka Therapeutics, Inc.) has 0 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.